{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:03:29Z","timestamp":1792253009346,"version":"4.4.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/fpc.0000000000000004","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T08:40:06Z","timestamp":1381221606000},"page":"611-618","source":"Crossref","is-referenced-by-count":15,"title":["Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol"],"prefix":"10.1097","volume":"23","author":[{"given":"Jolanta","family":"Wolkanin-Bartnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Pogorzelska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Szperl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Bartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Koziarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia T.","family":"Bilinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210213","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"R3-5-20210213","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.","volume":"96","author":"Taube","year":"2000","journal-title":"Blood"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy.","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"R15-5-20210213","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF03195700","article-title":"A vitamin K epoxyde reductase oxidase complex gene polymorphism (-1639GA) and interindividual variability in the dose effect of vitamin K antagonists.","volume":"50","author":"Stepien","year":"2009","journal-title":"J Appl Genet"},{"key":"R16-5-20210213","first-page":"397","article-title":"Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.","volume":"64","author":"Laszlo","year":"2006","journal-title":"Kardiol Pol"},{"key":"R17-5-20210213","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1160\/TH05-10-0678","article-title":"The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxyde reductase complex genes on warfarin dose requirement.","volume":"95","author":"Herman","year":"2006","journal-title":"Thromb Haemost"},{"key":"R18-5-20210213","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1160\/TH08-04-0116","article-title":"Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.","volume":"100","author":"Beinema","year":"2008","journal-title":"Thromb Haemost"},{"key":"R19-5-20210213","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists.","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R24-5-20210213","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00129784-200404010-00005","article-title":"The use of vitamin K in patients on anticoagulant therapy: a practical guide.","volume":"4","author":"Hanslik","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"key":"R25-5-20210213","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/j.1538-7836.2007.02715.x","article-title":"Daily vitamin K supplementation improves anticoagulant stability.","volume":"5","author":"Rombouts","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R27-5-20210213","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1525-139X.2003.03011.x","article-title":"The effect of chronic renal failure on hepatic drug metabolism and drug disposition.","volume":"16","author":"Dreisbach","year":"2003","journal-title":"Semin Dial"},{"key":"R28-5-20210213","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.V122326","article-title":"Downregulation of hepatic cytochrome P450 in chronic renal failure.","volume":"12","author":"Leblond","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R31-5-20210213","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","article-title":"CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.","volume":"83","author":"Caraco","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R34-5-20210213","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann Intern Med"},{"key":"R36-5-20210213","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1740774510381285","article-title":"Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.","volume":"7","author":"Joo","year":"2010","journal-title":"Clin Trials"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T07:05:39Z","timestamp":1646723139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201311000-00005"}},"subtitle":["dosing calculation algorithm"],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000004","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}